Clinical trials: Diffuse Large-Cell Lymphoma
Fever, Sweats, and Hot Flashes, Infection
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
RATIONALE: Recombinant human mannose-binding lectin (MBL) may be effective in preventing infection in young patients with fever and neutropenia receiving chemotherapy for blood disease or cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00886496
- Testing
- recombinant human mannose-binding lectin
- Where
- 3 sites in United States
- Sponsor
- Enzon Pharmaceuticals, Inc.
Diffuse Large B-Cell Lymphoma
MabionCD20 Compared to MabThera in Lymphoma Patients
The aim of the study is to demonstrate the high level of biosimilarity between MabionCD20 (MABION SA) and the reference product: MabThera (rituximab by Hoffman-La Roche) in patients with CD20-positive diffuse large B-cell…
- Trial name
- MADILYM (NCT02617485)
- Testing
- Rituximab, Doxorubicin, Vincristine
- Where
- 35 sites in Bosnia and Herzegovina, Croatia and 5 more
- Volunteers
- 143 people
- Sponsor
- Mabion SA
Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
This open-label, Phase I study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0853 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
- Trial name
- NCT01991184
- Testing
- GDC-0853
- Where
- 10 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Expanded Access Program for Epcoritamab
The purpose of this program is to provide investigational epcoritamab, an antibody also known as GEN3013 (DuoBody-CD3xCD20), in an expanded access setting for eligible patients with relapsed and/or refractory (R/R) large B-cell…
- Conditions
- Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
- Trial name
- NCT05733650
- Testing
- Epcoritamab
- Sponsor
- Genmab
Diffuse Large B-Cell Lymphoma
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) in participants with relapsed or refractory…
- Trial name
- POLARGO (NCT04182204)
- Testing
- Polatuzumab Vedotin, Rituximab, Gemcitabine
- Where
- 62 sites in United States, Brazil and 14 more
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, B-Cell
A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
This open-label, multicenter study will evaluate the efficacy and safety of obinutuzumab [RO5072759 (GA101)] in combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemotherapy in patients with advanced…
- Trial name
- NCT01414855
- Testing
- obinutuzumab, cyclophosphamide, doxorubicin
- Where
- 38 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06870487
- Testing
- PF-08046032, Sasanlimab
- Where
- 4 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- Pfizer
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
- Conditions
- Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- CERTAIN (NCT04526834)
- Testing
- CD30.CAR-T
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tessa Therapeutics
B-Cell Lymphomas
Long-term Registry of Patients Treated With Loncastuximab Tesirine
Retrospective and prospective multi-center observational study of patients with B-cell lymphomas treated with loncastuximab tesirine treatment in real-world practice.
- Trial name
- NCT05160064
- Where
- United States
- Sponsor
- ADC Therapeutics S.A.
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
The goal of the study is to identify a dose and schedule of CC-486 that can be safely administered with R-CHOP. To evaluate the safety and maximum tolerated dose (MTD) or the maximal administered dose (MAD) of CC-486 in…
- Trial name
- NCT02343536
- Testing
- Oral Azacitidine, Rituximab, cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 59 people
- Sponsor
- Celgene
Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
This is a phase I, open-label, first-in-human study of CS08399, comprising two phases: dose escalation (including single-dose and multiple-dose) and cohort expansion.
- Conditions
- Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma
- Trial name
- NCT07583771
- Testing
- CS08399
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Diffuse Large B Cell Lymphoma
A Study of ICP-022 in Patients With R/R DLBCL
It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL.
- Trial name
- DLBCL (NCT04438005)
- Testing
- ICP-022
- Where
- 7 sites in China
- Volunteers
- 3 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Lymphoma, Non Hodgkin
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
This open-label, single-arm, phase IIIb study will evaluate the safety of switching from intravenous (IV) to subcutaneous (SC) administration of rituximab during first-line treatment for participants with CD20+ non-Hodgkin's…
- Trial name
- NCT01987505
- Testing
- Rituximab
- Where
- 39 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, Large-cell Lymphoma
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
Phase 1 study to assess the safety, preliminary efficacy of CD19 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with diffuse large B-cell lymphoma (DLBCL).
- Conditions
- Diffuse Large B Cell Lymphoma, Large-cell Lymphoma, Lymphoma, B-Cell, Lymphoma
- Trial name
- NCT04052061
- Testing
- CD19 t-haNK
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL
The goal of this project is to test the feasibility of a Patient Preferences in Shared Decision-Making encounter tool (PPSDM) in the clinical context of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL).
- Trial name
- NCT04160442
- Testing
- Carevive CarePlanning System
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Carevive Systems, Inc.
Diffuse Large B-Cell Lymphoma
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R)…
- Trial name
- Javelin DLBCL (NCT02951156)
- Testing
- Avelumab, Utomilumab, Rituximab
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 29 people
- Sponsor
- Pfizer
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
This is a Phase 1, open-label, two-part, safety, PK, and activity study designed to characterize the DDI potential of tazemetostat. Tazemetostat will be taken orally BID continuously in 28-day cycles in both study parts.
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma, Advanced Solid Tumor
- Trial name
- NCT03028103
- Testing
- Tazemetostat, Fluconazole, Omeprazole
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Epizyme, Inc.
Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
This study has 3 parts. The purpose of Part 1 of this study is to assess the safety and efficacy of brentuximab vedotin in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (known as…
- Trial name
- NCT01925612
- Testing
- brentuximab vedotin, rituximab, vincristine
- Where
- 51 sites in United States, Czechia and 3 more
- Volunteers
- 87 people
- Sponsor
- Seagen Inc.
Advanced Solid Tumors, Aggressive B-cell Lymphomas
A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736 (durvalumab), or rituximab in participants with either…
- Trial name
- MEDI6469 (NCT02205333)
- Testing
- MEDI6469 Monotherapy, MEDI6469 Plus Tremelimumab, MEDI6469 Plus Durvalumab
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- MedImmune LLC